Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218817

SCHEMBL23218817

SCHEMBL23218817

CCOC(=O)Cc1ccccc1OCc1nnc2ccc(Cl)cn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A2 P11168 1/20 0.46
▸ TBXAS1 P24557 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.43
▸ GAA P10253 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CFD P00746 1/20 0.39
▸ PTGER1 P34995 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ MET P08581 2/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853185 1.00 SLC2A2 (0.46) SLC2A2TBXAS1ALDH1A1GAACYP1A2
SCHEMBL29852984 0.80 CFD (0.56) SLC2A2TBXAS1CFDMET
SCHEMBL23218082 0.80 CFD (0.56) SLC2A2TBXAS1CFDMET
SCHEMBL21439500 0.72 CFD (0.51) SLC2A2TBXAS1ALDH1A1CYP1A2CYP2C9
SCHEMBL7890168 0.72 TBXAS1 (0.59) TBXAS1ALDH1A1GAAKDM4EMAPT
SCHEMBL23219125 0.71 TBXAS1 (0.45) SLC2A2TBXAS1ALDH1A1GAAKDM4E
SCHEMBL29852848 0.71 TBXAS1 (0.45) SLC2A2TBXAS1ALDH1A1GAAKDM4E
SCHEMBL5661211 0.71 TBXAS1 (0.53) TBXAS1ALDH1A1GAAMAPTMAPK1
SCHEMBL21439042 0.71 TBXAS1 (0.49) SLC2A2TBXAS1TP53CFDPTGER1
SCHEMBL21438924 0.71 TBXAS1 (0.49) SLC2A2TBXAS1ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB SLC2A2 2603/4885TBXAS1 963/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB SLC2A2 3887/4885TBXAS1 392/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.